First human use of the Hemopump, a catheter-mounted ventricular assist device
| Autor: | Wayne E. Dear, O.H. Frazier, Michael P. Macris, John M. Fuqua, Richard K. Wampler, Steven M. Parnis, J. Michael Duncan |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Cardiac output Cardiac Catheterization Time Factors medicine.medical_treatment Cardiac index Shock Cardiogenic Hemolysis law.invention Electrocardiography Catheters Indwelling Electric Power Supplies law medicine.artery Internal medicine Ascending aorta medicine Cardiopulmonary bypass Humans Myocardial infarction Cardiac Output Aged Monitoring Physiologic business.industry Heparin Cardiogenic shock Equipment Design Middle Aged medicine.disease Surgery Ventricular assist device Cardiology Female Heart-Assist Devices Cardiology and Cardiovascular Medicine business Hemopump |
| Zdroj: | The Annals of thoracic surgery. 49(2) |
| ISSN: | 0003-4975 |
| Popis: | The Hemopump, a catheter-mounted, temporary ventricular assist device, consists of an external electromechanical drive console and a disposable, intraarterial axial-flow pump (21F). Power is transmitted percutaneously to the pump by a flexible drive shaft within the catheter. The device is positioned in the left ventricle by way of the femoral artery approach or through the ascending aorta. Blood is drawn from the left ventricle through the transvalvular inlet cannula and pumped into the aorta. As of December 1988, the Hemopump had successfully supported the circulation of 7 patients (5 men, 2 women) ranging in age from 44 to 72 years (mean age, 59 years) and suffering from cardiogenic shock (cardiac index less than 2.0 L/min/m2). Indications for use included failure to be weaned from cardiopulmonary bypass in 4 patients, acute myocardial infarction in 1, severe cardiac allograft rejection in 1, and donor heart failure in 1. Duration of support ranged from 26 to 113 hours (mean, 66 hours). Although 5 patients demonstrated transient hemolysis, none experienced infection, thrombosis, or vascular injury. Hemodynamic variables improved in all patients during support by the device. As of December 1988, 5 of the 7 patients were alive more than 30 days after support had been discontinued, and 3 of these patients were discharged from the hospital. On the basis of our initial clinical results, the Hemopump, which does not require a major surgical procedure for insertion, provides effective, temporary circulatory support in patients with potentially reversible cardiac failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|